Tampere University Biomaterials and Tissue Engineering Master's Thesis Guide: 30 ECTS, BBT.MJS.111 and Trepo

Quick answer: what is the Biomaterials and Tissue Engineering thesis route?

Tampere University’s Biomaterials and Tissue Engineering study option is a 120 ECTS Master of Science (Technology) route in the Master’s Programme in Biomedical Sciences and Engineering. The current degree page states explicitly that the master’s thesis carries 30 ECTS. Because the degree is MSc (Technology), the thesis follows Tampere’s Technology thesis process and is graded 0-5.

The current field-specific advanced-studies module is BSEM-S01 Advanced Studies in Biomaterials and Tissue Engineering, at least 80 ECTS. Thesis preparation is not borrowed from CSEE. The programme has its own current BBT.MJS.111 Master’s Seminar, Biomedical Sciences and Engineering, 2 ECTS, pass/fail. Its completion option explicitly includes students making a thesis in Biomaterials and Tissue Engineering, and all parts are compulsory, including a 0 ECTS information-searching skills component.

1. Understand the degree object before adding credits

The current Sisu structure exposes both BSEM.BTE, labelled at least 120 credits, and BSEM-S01, labelled at least 80 credits. Do not add those labels mechanically to the 120-credit degree. BSEM.BTE is a broad programme/specialisation object, while the degree programme itself is 120 ECTS and separately states that the thesis carries 30 credits.

For an individual study plan, use the exact Sisu structure that applies to your admission cohort. The safe thesis facts for the current 2026-2027 curriculum are the 30 ECTS thesis and the current BBT.MJS.111 seminar route.

2. What the specialisation actually covers

Tampere describes the specialisation at the interface of engineering and health sciences. Students develop knowledge of biomedical-material synthesis and characterisation, interfaces between materials/devices and biological systems, implant design, disease modelling, tissue replacement or repair, stem-cell technology, scaffold design, tissue functionality, clinical outcomes and regulation.

BSEM-S01 also emphasises the integrated roles of cells, biomaterials, biophysical and chemical signals and growth factors. It asks students to consider ethical and legal aspects of tissue-engineered products in clinical use. A thesis can therefore be strongly materials-oriented, strongly biological, or intentionally interdisciplinary, but its research question must make the evidence level clear.

3. Use BSEM-S01 as the advanced-studies anchor

BSEM-S01 is current through 2026-2027 and is at least 80 ECTS. It develops a biomaterials foundation and then extends toward tissue engineering, including living cells and biological cues. This makes it a useful academic anchor for thesis topics, but the module title alone does not tell you which exact courses are compulsory in your personal plan.

Do not claim that every BTE thesis must use cells, stem cells, scaffolds or transplantation models. Those are programme domains. The thesis method still follows the research question, available infrastructure, ethics and supervision.

4. BBT.MJS.111 is the current thesis seminar

BBT.MJS.111 Master’s Seminar, Biomedical Sciences and Engineering is 2 ECTS and pass/fail. Its current completion option explicitly lists Biomaterials and Tissue Engineering among the thesis areas it serves. The course teaches the thesis process, scope control, good writing practices, presentation skills and familiarity with other theses in the field.

The current English seminar runs across the 2026-2027 academic year. All parts of the completion option are compulsory. The associated information-searching skills component is 0 ECTS, pass/fail and covers systematic searching, search strategies and diaries, source evaluation, citation chains, ethical use of information, open publishing and data-management considerations.

5. The thesis itself is 30 ECTS and 0-5 graded

The current Biomedical Sciences and Engineering degree page says the master’s thesis carries 30 credits and can be tailored toward an academic, industrial or hospital-oriented career. Tampere’s Technology thesis framework governs supervision, the supervision plan, preliminary review, originality checking, Trepo submission and examination.

The Technology thesis is graded on the 0-5 scale. Keep this separate from BBT.MJS.111, which is pass/fail. Passing the 2 ECTS seminar does not determine the thesis grade.

6. Start with a bounded research claim, not a broad medical promise

“Develop a new scaffold”, “test a biomaterial” or “improve tissue regeneration” is too broad as a thesis question. State what property or mechanism you are evaluating and in what model. For example, a thesis may ask whether a defined material modification changes a measured surface property and whether that change is associated with a bounded cell response under specified in-vitro conditions.

The claim should determine the experiment. If the endpoint is mechanical integrity, design a mechanical validation. If the endpoint is cell viability or differentiation, define the biological assay and model. If the contribution is synthesis or material characterisation, do not inflate it into a clinical-effectiveness claim.

7. Separate material synthesis from biological evaluation

A biomaterial thesis often contains several evidence layers: how a material was made, what physical/chemical properties it has, how a biological model responded, and what those observations may imply for future application. Report those layers separately.

For synthesis or fabrication, document composition, reagents/material sources, processing route, curing/crosslinking or other relevant conditions and any post-processing that could change the sample. For commercial materials, record enough product and lot information to explain variation without disclosing restricted information unnecessarily.

8. Characterisation should match the research question

Current BBT.034 Medical Biomaterials grounds the field in material classes, biocompatibility and tissue/material interactions. A thesis should select characterisation methods because they test a hypothesis, not because instruments are available.

If surface chemistry is claimed to drive cell behaviour, characterise the relevant surface. If stiffness is central, measure mechanical properties under conditions that represent the claim. If porosity or scaffold architecture is central, quantify it using a reproducible approach. Do not use a long instrument list as a substitute for an evidence chain.

9. Biocompatibility is not a single universal property

“Biocompatible” can become an overclaim. Response depends on material composition, surface state, degradation products, dose/exposure, tissue/cell model and endpoint. One viability assay in one cell line does not prove general compatibility for all clinical contexts.

State exactly what was tested: for example, cytotoxicity under a specified extract condition, adhesion on a defined surface, inflammatory-marker expression in a particular cell model, or a mechanical response in a particular tissue-mimicking setup. Keep the conclusion at that evidence level.

10. Cell source, passage and biological context matter

If the thesis uses cells, document the cell type/source and the factors that materially affect reproducibility. Depending on the model, this may include donor/source, passage range, differentiation state, seeding density, media, supplements, surface coating and culture duration.

Do not treat repeated wells from one preparation as independent biological evidence. Distinguish technical replicates from biological replicates and define the true experimental unit before statistical analysis.

11. Stem-cell work needs especially careful claim boundaries

The programme explicitly includes stem-cell technology. Stem-cell experiments can be highly sensitive to culture history, differentiation protocol and batch effects. Define the starting cell population, protocol, time points and markers used to infer differentiation or phenotype.

Marker expression can support a bounded biological conclusion, but it does not automatically prove mature tissue function. If function is the claim, include an appropriate functional endpoint or state clearly that the work is limited to molecular, morphological or early phenotypic evidence.

12. Scaffold design: geometry is part of the method

Scaffold research should describe geometry/architecture, material composition, fabrication parameters and conditioning. Pore size, porosity, fibre orientation, crosslinking, swelling and degradation can influence both mechanics and cell behaviour.

If a manufacturing process produces substantial sample-to-sample variation, measure and report it. A single “representative” scaffold image is not a population estimate. Connect structure to the exact performance claim instead of presenting microscopy only as illustration.

13. Mechanical testing must be reproducible

For tensile, compression, indentation or other mechanical tests, report sample geometry, conditioning state, loading mode, strain/loading rate and analysis method when relevant. Hydrated biological materials can behave differently from dry samples, so describe the state actually tested.

If you compare groups, keep testing conditions consistent. If samples have different geometry, explain normalisation. When failure mode matters, record it rather than reporting only a peak value.

14. Microscopy and image analysis need an audit trail

Microscopy figures are often persuasive but vulnerable to selection bias. Record acquisition settings, field-selection logic and image-processing steps. If images are quantified, define segmentation thresholds, regions of interest, exclusion criteria and whether the analysis was blinded or standardised.

Multiple fields from one sample are usually subsamples, not independent biological replicates. Preserve the hierarchy between images, samples, donors/batches and experimental groups in both statistics and figure captions.

15. Controls and baselines must test the claim

Choose controls based on the mechanism. Depending on the experiment, useful controls may include untreated cells, reference materials, material-only controls, vehicle controls, blank scaffolds or a clinically established material.

A control is not automatically “positive” or “negative” simply because it is familiar. Explain what result the control should produce and what failure of that control would mean for the experiment.

16. Replicates, experimental units and statistics

Before collecting data, define the experimental unit. If one cell preparation is divided into twelve wells, those wells may improve measurement precision but do not necessarily create twelve independent biological samples. Pseudoreplication can make confidence look stronger than the design supports.

Report biological and technical replication separately. For quantitative comparisons, report effect sizes and uncertainty where appropriate. If many endpoints are explored, distinguish planned primary outcomes from exploratory findings and avoid selecting only favourable measurements.

17. Batch effects are a first-class variable

Biomaterials and cell experiments can vary by reagent lot, biomaterial batch, donor, cell passage, scaffold fabrication run, operator or day. Track those sources of variation during the experiment rather than trying to reconstruct them after unexpected results.

If multiple batches are used, balance study groups across batches where feasible. If a conclusion depends on one batch or one donor, state that limitation explicitly.

18. Degradation, release and time-course studies

If the material degrades, releases a factor or changes during culture, the sampling schedule should follow the expected mechanism. Record media volume, exchange schedule, temperature and other relevant exposure conditions.

A single endpoint can miss transient behaviour. Conversely, a dense time course without a biological rationale creates many comparisons. Choose time points that answer the research question and document how repeated measurements are handled statistically.

19. Disease models and tissue-function claims

Tampere links the programme to disease modelling and tissue replacement/repair. Define what your model actually represents. Does it reproduce one molecular pathway, a tissue phenotype, a mechanical environment or a treatment response?

A laboratory model is useful because it is simplified. Its limitations should therefore be explicit. If the model lacks immune, vascular, neural or mechanical components relevant to clinical tissue, do not generalise beyond the model without supporting evidence.

20. Translational claims need evidence-level labels

The programme is strongly translational, from laboratory toward clinical contexts. A thesis should distinguish material feasibility, in-vitro biological response, preclinical relevance, regulatory relevance and clinical outcome evidence.

A promising laboratory result can justify further research, but it does not establish safety, effectiveness or regulatory approval. If a discussion section considers clinical translation, label it as interpretation and future work rather than a result produced by the thesis.

21. Human cells, tissues and participant-derived material

Tampere’s research-ethics framework requires the applicable ethical and legal route to be resolved before research involving humans or human-derived materials where such requirements apply. Medical research involving humans is regulated separately under Finnish law and related regulations.

Do not assume that material already present in a laboratory can automatically be used in a student thesis. Confirm with the supervisor what approval, consent, biobank/tissue permission, research permission, data-processing basis and reporting restrictions apply to the exact material and purpose.

22. Animal research has its own legal framework

Tampere states that animal research is governed by legislation on animals used for scientific and educational purposes. A master’s thesis should only use animal experiments or animal-derived research through the approved institutional project and supervision arrangements that apply to that work.

Do not design an animal protocol independently from online sources or from a thesis manuscript. The thesis should report the approved model and relevant methodological details without exposing restricted facility information.

23. Personal data and coded biological data

Biological samples can be linked to personal information directly or indirectly. Tampere’s student data-protection guidance applies when thesis work processes personal data. Clarify who is the data controller, what data are needed, how identifiers are handled, access rights, retention and what can appear in the public thesis.

Pseudonymised data are not automatically anonymous. If a code can be linked back to a person, treat the data according to the applicable personal-data rules.

24. Laboratory safety and biosafety are part of method quality

Chemical synthesis, cell culture, biological material and specialised equipment require laboratory-specific safety procedures. Use the hosting research group’s approved protocols, training, biosafety practices and waste rules.

The thesis should describe relevant safety constraints when they influence experimental design, but it should not become a substitute laboratory manual. If a hazardous condition limits the feasible operating range, report that limitation rather than bypassing controls to obtain a result.

25. Reproducibility: connect notebooks to final figures

Maintain identifiers that connect raw material/cell/sample records to instrument files, processed datasets, analysis scripts, figures and tables. Record relevant reagent lots, material batches, cell passages and software versions.

For image analysis or computational modelling, version thresholds, scripts and parameters. A final figure should be traceable to the underlying raw data and processing decisions without relying on memory.

26. AI use: protect data and verify scientific content

Tampere permits AI support under current study guidance, but the student remains responsible for the work. Agree thesis-specific AI principles with the primary supervisor and follow acknowledgement rules.

Do not upload confidential laboratory data, unpublished partner results, patient/participant information or protected material to external AI services without an approved basis. Verify AI-generated literature summaries, citations, equations, code and biological explanations against primary sources and your own analysis.

27. Supervision plan and project dependencies

Technology thesis students prepare a Thesis Supervision Plan with the supervisor. Use it to define scope, meeting practices, milestones and responsibilities. For BTE, also record dependencies such as cell/material availability, ethics/permission timing, laboratory access, shared equipment, long culture periods and assay lead times.

Have a fallback plan. If a cell source fails or an instrument becomes unavailable, decide whether the thesis can answer a narrower question using existing data, alternative characterisation or a literature/computational route.

28. Writing while experiments are running

Write methods while protocols are still fresh. Maintain a results ledger linking every figure to the experimental question. Separate observations from interpretation: first describe what changed, then discuss the mechanism and competing explanations.

A negative or null result can still be a valid thesis result if the study was well designed. Do not silently remove unfavourable batches or endpoints. Explain exclusions using pre-defined or scientifically defensible criteria.

29. Maturity test, Turnitin, Trepo and PDF/A

A maturity test is part of the master’s-thesis process. For international master’s students in Technology, Tampere’s current guidance states that the thesis abstract serves as the maturity test, with content assessed by the examiner; students with a different language route should follow the applicable current instructions.

After primary-supervisor permission, the final thesis goes through Turnitin and supervisor review, then is deposited in Trepo for formal examination. The student must be registered as attending to submit and receive credits. Prepare the final file as valid PDF/A for permanent archiving.

30. Examination, grading and timing

The Technology thesis is graded 0-5. Tampere’s normal examiner window is 21 days, extended to 28 days when a separate maturity test is required as part of the process. These are assessment windows, not guarantees for the whole graduation process.

The examiner statement and proposed result are sent to the student’s tuni.fi email. Plan backwards from graduation deadlines and leave time for preliminary review, revisions, Turnitin, Trepo access and faculty processing.

31. Final Biomaterials and Tissue Engineering checklist

Before starting, verify your current BSEM-S01, 30 ECTS thesis, BBT.MJS.111 seminar and 0 ECTS information-searching component in Sisu. Confirm supervisor(s), topic, approvals/permissions, data roles, laboratory access and whether human, animal or restricted material is involved.

Before submission, confirm that material and biological evidence are not conflated; experimental units and replicates are correct; batches/donors/passages are traceable; controls test the claim; microscopy and statistics are reproducible; translational claims match the evidence level; personal/restricted data are protected; AI use is compliant; seminar and maturity requirements are complete; Turnitin is reviewed; PDF/A is valid; Trepo submission is complete; and the timetable leaves room for examination.

A strong BTE thesis does not need the broadest possible medical promise. It needs a bounded scientific or engineering question, transparent material and biological methods, correct experimental units, traceable evidence and conclusions that stop exactly where the data stop.

One final structural check matters before you lock the study plan: the 30 ECTS thesis and BBT.MJS.111 2 ECTS pass/fail seminar are separate current objects. BBT.MJS.111 is the Faculty of Medicine and Health Technology route that explicitly serves Biomaterials and Tissue Engineering students. Do not import CSEE’s ITC.CEE.800 or a CSEE seminar merely because other Tampere MSc (Technology) programmes use them. Confirm that your own Sisu plan still shows BBT.MJS.111 and its compulsory 0 ECTS information-searching component for the relevant curriculum year.

For the final discussion, use an evidence ladder. Material chemistry or mechanics can support a material-level claim; cell assays can support a bounded biological-response claim; tissue-model function can support a model-level claim; none of these alone proves a clinical outcome. If the thesis includes several layers, state clearly where each conclusion comes from and which additional evidence would be required before moving toward preclinical, regulatory or clinical claims. This makes the 30 ECTS project scientifically ambitious without making its conclusions stronger than the experiment.